RE: Update22 Apr 2026 08:54
UBS sold out
Excellent rns
The transition also delivers immediate cost efficiencies, materially reducing the Company's fixed cost base in the near term, with the potential to generate substantial longer-term value with expected cost savings of over $2.6 million on a net present value basis over five years. The reduced cost base is expected to deliver immediate gross margin gains and drive meaningful operating leverage as testing volumes scale.
Additionally, the Company announces that it has completed, to schedule, the submission for CE marking of the technical file for kidneyintelX.dkd. As previously announced, achievement of CE marking is a core strategy to enable use of kidneyintelX.dkd in global pharma clinical trials while at the same time, enabling commercialisation of kidneyintelX.dkd in certain European markets. The Company expects to finalise the CE marking process in Q3 2026 with initial testing of patients and data generation from the Steno Diabetes Center expected in Q4 2026 and expanding to services revenue generating testing at multiple sites in 2027.